Mirtazapine Cadila Pharmaceuticals (Europe)

Mirtazapine, the active ingredient in Mirtazapine Cadila Pharmaceuticals (Europe), is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Cadila Pharmaceuticals (Europe) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used primarily within the depressive disorder therapeutic area. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive episodes with anxiety: alleviates both mood and anxiety components. - Treatment‑resistant depression (adjunct): may be added when first‑line antidepressants are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or somnolence - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension - Seizures - Hepatic dysfunction

Before initiating therapy, clinicians should consider several safety aspects. - Monitor weight: patients often experience increased appetite and weight gain; regular weight checks are advised. - Assess mood changes: watch for emergence of suicidal thoughts, particularly during the first weeks. - Evaluate hepatic function: dose adjustment may be needed in severe liver impairment. - Caution in the elderly: increased risk of sedation and falls; start at low doses. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin syndrome potential. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect; monitor blood pressure. - Anticholinergic drugs: increased anticholinergic burden may worsen dry mouth and constipation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels; consider dose adjustment.